Thalidomide in multiple myeloma: current status and future prospects.
about
Bortezomib: the evidence of its clinical impact in multiple myeloma.Management of thalidomide toxicity.PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.Thalidomide for the treatment of multiple myeloma.Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.Evolving treatment strategies for myeloma.Thalidomide and immunomodulatory drugs in the treatment of cancer.Current treatment options for myeloma.The future role of thalidomide in multiple myeloma.Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis.A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.Bortezomib for multiple myeloma.Thalidomide in multiple myeloma: past, present and future.An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myelomaCurrent trends in multiple myeloma management.Thalidomide-induced sinus bradycardia.Acute Pulmonary Toxicity from Thalidomide in a Patient with Multiple Myeloma.Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.Early response predicts thalidomide efficiency in patients with advanced multiple myeloma.Guidelines on the diagnosis and management of AL amyloidosis.Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma.Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis.The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio.Guidelines on the diagnosis and management of multiple myeloma 2005.Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism.
P2860
Q33400724-4E617D48-C1B0-4FEA-8614-B2CB6C140497Q34343991-77776C8C-DEE6-4D03-B4AA-04F0073F37C4Q34426066-89B597B2-4FAB-44D4-8C24-71FDE92574BAQ35870500-1580BA82-B90A-4A51-86C4-34307B44408DQ35904262-3F273B61-80FE-410D-8389-8498A390EB5AQ36012354-A347901B-9C92-4A5F-8F2F-059816F16EFCQ36040871-94B2B38B-5E03-4AAA-80A1-B4AC0BFBCA6FQ36163971-FB259525-EA62-40E8-A2B3-3094F301F1BFQ36258705-00F08EC5-F053-4538-9565-B6C16FF7DCD4Q36303471-C7FDDE91-8FD6-44AD-822A-09426A42410DQ36381565-5D2D7E95-041B-445A-95CE-0A69B5701881Q36521862-C54186BB-54E7-4B36-A4B6-1FD319D1D0C2Q36616493-4551F65F-9A75-4B37-8373-373064DD1A42Q36695180-7A122BEA-47C0-416E-A66B-02B27C81B1FCQ37183557-13980811-1D55-4811-8EF9-37851DB0EAB7Q42166156-7C00CA34-E3BA-4C8A-947C-5EF89D901FC2Q42743555-B0237A40-5639-4334-A332-801B8CE24399Q44537656-C79BC854-0DA6-4D19-A45F-1A31EF127AB9Q44826295-91C44F1C-DF7D-4293-BE98-4F40DC96906FQ44924110-12AA3CBB-A879-4C41-A64E-84C13D3A8C65Q45095148-F41F4470-D7B3-4058-9D9D-D90FD06716CEQ45128205-A5FC40DC-844C-4078-93AE-73110A34B28AQ46389744-1E1F949F-1650-42DF-B1B2-D794C897CD3AQ46634193-EADAC9E3-946C-42F2-B84E-3F7BE82B839BQ53556535-A5069170-CFB5-4447-9E97-ABD41A57B978Q53584702-B209FC1C-432A-4B94-991A-A20AF8DE1A4C
P2860
Thalidomide in multiple myeloma: current status and future prospects.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Thalidomide in multiple myeloma: current status and future prospects.
@en
type
label
Thalidomide in multiple myeloma: current status and future prospects.
@en
prefLabel
Thalidomide in multiple myeloma: current status and future prospects.
@en
P2093
P1476
Thalidomide in multiple myeloma: current status and future prospects.
@en
P2093
Heather Oakervee
Jamie D Cavenagh
UK Myeloma Forum and the BCSH Haematology/Oncology Task Forces
P356
10.1046/J.1365-2141.2003.03902.X
P407
P577
2003-01-01T00:00:00Z